Sentences with phrase «from other cancer patients»

«We will then use this technique to explore prostate tissues from other cancer patients.

Not exact matches

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

This surgeon was one of the best in this field and had even successfully tried a treatment on this exact cancer for other patients that tripled the five - year - survival odds — from 5 percent to 15 percent — albeit with a poor quality of life.

I can't imagine how good it must feel to receive some of those emails from cancer patients or others who are sustained by his product.

Critics say an oils - only approach would provide relief for some kids suffering from seizures, but would be of little benefit to cancer and other patients with chronic pain who use marijuana for immediate relief.

Mr. Cuomo said he will use an executive order to revive the Antonio G. Olivieri controlled substances therapeutic research program, which was established by law in 1980 and discontinued soon after, and allow up to 20 hospitals to dispense marijuana to approved patients suffering from cancer and other serious illnesses.

And using cells from someone other than the cancer patient being treated might trigger an immune response against the foreign cells.

Future resources from the NCI Center for Cancer Genomics (CCG), which oversees TCGA and other activities, will support more translationally focused research, including databases with genomic information on clinical samples linked to outcomes of their patient donors.

Metastatic pancreatic cancer — cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths — changes its metabolism and is «reprogrammed» for optimal malignancy, according to new findings reported Jan. 16 in Nature Genetics.

Medical scientists, on the other hand, are crunching billions of data points culled from millions of patients about genetic mutations that make people more vulnerable to diseases like diabetes, heart disease and cancer.

«Our research paves the way for future clinical trials that screen for AIM2 expression in colon cancer and possibly other cancers to identify patients who may potentially benefit from personalized anti-Akt therapy,» Wilson said.

Many patients with low - risk prostate cancer have a lower risk of dying from prostate cancer than from other causes.»

By linking these layers and others to expand from genomics to multi-omics, scientists might be able to meet the goals of personalized medicine: to figure out, for example, what treatment a particular cancer patient will best respond to, based on the network dynamics responsible for a tumor.

While clinical trials of such immunotherapies in other cancers have shown them to be highly effective in a subgroup of patients, the new study stands out because nearly all patients benefited from the treatment.

Diabetes is linked to an increased risk of developing cancer, and now researchers have performed a unique meta - analysis that excludes all other causes of death and found that diabetic patients not only have an increased risk of developing breast and colon cancer but an even higher risk of dying from them.

To evaluate sensitivity and specificity of the device, Tyburski studied blood taken from 238 patients, some of them children at Children's Healthcare of Atlanta and the others adults at Emory University's Winship Cancer Institute.

White and colleagues will work with other collaborators at the Cancer Institute to develop early - phase patient clinical trials based on the findings from this study in the near future.

The research team with international collaborators analysed more than 100 patient samples from ovarian and other cancer types to discover a distinct population of cells found in some tumours.

Results reveal that on average, the 13 states allowing the use of medical marijuana had a 24.8 percent lower annual opioid overdose mortality rate after the laws were enacted than states without the laws, indicating that the alternative treatment may be safer for patients suffering from chronic pain related to cancer and other conditions.

Monitoring immune cell activity — including phenotyping immune cell subsets, tracking cell proliferation, and measuring cytokine production — can provide insights into the overall status of immune function in patients, particularly those undergoing immunosuppression after transplants, enduring cancer treatment, or suffering from autoimmune disease or other pathologies that affect the immune system.

The second question is more difficult to answer than it might seem because the low prevalence of cancer and diabetes in Laron patients is counterbalanced by an abnormally high risk of death from other causes, especially accidents, alcohol, and convulsive disorders.

The team chose to compare breast tissue from healthy individuals with tumor samples taken from breast cancer patients — including both primary tumors that had not spread from the breast to other body sites, and highly aggressive, metastatic tumors.

At the Johns Hopkins Hospital and three other hospitals, researchers conducted surveys and took oral rinse samples from 166 male and female patients with HPV - related oropharyngeal cancers and 94 spouses and partners.

Abatacept, when added to the standard drug regimen used to prevent GvHD, reduced the occurrence of acute, grade III - IV GvHD from 32 to 3 percent in pediatric and adult patients who underwent mismatched unrelated donor stem cell transplants to treat advanced cancer and other blood disorders.

Unlike other solid tumors, there has been limited progress in understanding the contribution of genetic risk factors to the development of uveal melanoma, researchers say, primarily due to the absence of comprehensive genetic data from patients as the large sample cohorts for this rare cancer type have not been available for research.

When tested on various cancer patient databases, iCAGES was found to be superior to other computational tools at predicting cancer drivers from personal genomes and at identifying beneficial treatment.

Analyzing the poly - G profiles of primary and metastatic colon cancer samples from 22 patients revealed that how the primary and metastatic tumors related to each other was different for each patient.

Previous in vitro studies conducted by researchers in other countries showed that this molecule was able to reduce the multiplication and increase the mortality of cells from melanoma, the most aggressive type of skin cancer, as well as breast cancer and neuroblastoma, a tumor that typically affects patients aged 15 or younger.

The study drilled down in particular on patients who had a high risk of dying from a cause other than prostate cancer within 10 years.

Perera began working with Weinstein on a small study comparing two groups of hospital patients: One group was suffering from lung cancer; the other was a group of orthopedic patients as a control sample.

Having only people with head and neck cancers in the study eliminates the variability of a group suffering from different forms of the disease, but it also eliminates information about whether patients with other forms of cancer would show the same results.

Triple - negative breast cancers do not benefit from the targeted therapies that have greatly improved the survival of patients with other subtypes of breast cancer.

His story inspired a book, The Forever Fix, which heralded the LCA trials as part of the wave of successes for gene therapy, which was recovering from several setbacks — including the death of a patient and cancer in others — in the late 1990s and early 2000s.

Researchers led by Van Allen and Choueiri sought an explanation for why some patients with a form of metastatic kidney cancer called clear cell renal cell cancer (ccRCC) gain clinical benefit — sometimes durable — from treatment with immune checkpoint inhibitors that block the PD - 1 checkpoint, while other patients don't.

The researchers also analyzed the effects of methylnaltrexone on another 135 patients from the same trials who had advanced illnesses other than cancer, such as congestive heart failure, advanced chronic obstructive pulmonary disease or neurologic diseases.

Colin Collins and Alexander Wyatt, and other researchers from the Vancouver Prostate Centre at the Vancouver Coastal Health Research Institute, matched 25 patients» treatment outcomes with the RNA sequence of their prostate cancer tumors.

«Without the context of a medical history of that patient, plus information from other clinical findings in relation to that patient, risk would be hard to assess,» says a spokesperson for University College London's Cancer Institute.

To explore this idea, Hopkins oncologists Dung Le, Luis Diaz, and others looked for mismatch repair mutations in tumor samples from patients with advanced colon cancer and other cancer types whose tumors had stopped responding to other treatments.

The patients selected from the Netherlands Cancer Registry had no metastases (spread of the cancer to organs other than the lymph nodes close to the tuCancer Registry had no metastases (spread of the cancer to organs other than the lymph nodes close to the tucancer to organs other than the lymph nodes close to the tumour).

After confirming in mouse models that cells from HER2 - positive breast cancers became resistant to anti-HER2 treatment when implanted into the brain but not into other tissues, the investigators found that HER3 is overexpressed in brain metastases of HER2 - positive breast cancers from both mice and human patients.

Professor Sabine Siesling, from the Netherlands Comprehensive Cancer Organisation (IKNL) and University of Twente and Mirelle Lagendijk, MD, from the Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands, and colleagues from other hospitals, studied survival nationwide in nearly 130,000 breast cancer patients, divided into two groups: those diagnosed between 1999 - 2005 and those diagnosed between 2006 -Cancer Organisation (IKNL) and University of Twente and Mirelle Lagendijk, MD, from the Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands, and colleagues from other hospitals, studied survival nationwide in nearly 130,000 breast cancer patients, divided into two groups: those diagnosed between 1999 - 2005 and those diagnosed between 2006 -Cancer Institute, Rotterdam, The Netherlands, and colleagues from other hospitals, studied survival nationwide in nearly 130,000 breast cancer patients, divided into two groups: those diagnosed between 1999 - 2005 and those diagnosed between 2006 -cancer patients, divided into two groups: those diagnosed between 1999 - 2005 and those diagnosed between 2006 - 2012.

Other blood disorders that have shown significant benefit from targeted gene therapy in small trials include hemophilia (specifically, factor IX deficiency), severe beta - thalassemia (deficiency for the adult beta - globin gene) and leukemia, where the patient's immune cells were treated to enable them to recognize cancer cells and destroy them.

Pediatric stem cell transplant and cancer patients often are discharged from the hospital with an external central venous line for medications that parents or other caregivers must clean and flush daily to avoid potentially life - threatening infections.

Dr James Larkin, a Consultant Medical Oncologist at The Royal Marsden, London, UK, told the 2015 European Cancer Congress [1], that results from the CheckMate 067 phase III clinical trial had already shown that the combination of the two drugs, which target two different pathways that regulate the immune system, improved the progression - free survival in patients with melanoma who had not received any other treatment.

Metastasis, the process by which cancer cells disseminate from their primary site to other parts of the body, leads to the death of most cancer patients.

«By further examining zinc metallochaperones on other p53 mutants that are similarly structured, we have an opportunity to increase the potential pool of patients that could theoretically benefit from zinc metallochaperones resulting in broad activity against all cancer types.

Jan. 19, 2017 — Metastatic pancreatic cancer — cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths — changes its metabolism and is «reprogrammed» for optimal malignancy, according to new findings reported Jan. 16 in Nature Genetics.

Since the advent of PSA screening, the incidence of patients presenting with advanced prostate cancer has declined remarkably and death rates from prostate cancer as reported in the National Cancer Database have declined at the rate of 1 % per year since 1990.56 Other data indicate similar declines in prostate cancer related mortality in tcancer has declined remarkably and death rates from prostate cancer as reported in the National Cancer Database have declined at the rate of 1 % per year since 1990.56 Other data indicate similar declines in prostate cancer related mortality in tcancer as reported in the National Cancer Database have declined at the rate of 1 % per year since 1990.56 Other data indicate similar declines in prostate cancer related mortality in tCancer Database have declined at the rate of 1 % per year since 1990.56 Other data indicate similar declines in prostate cancer related mortality in tcancer related mortality in the US.

These drugs free a patient's immune system from cancer - induced suppression, while others engineer a patient's own white blood cells to attack cancer.

Dr Behren, Professor Jonathan Cebon, Mr Dani Tutuka and others from the ONJCRI examined whether these new - generation BRAF inhibitors could be successfully used to treat melanoma patients without unintentionally accelerating the growth of other cancers, including colorectal cancers.